Suppr超能文献

垂体腺瘤切除成功后“治愈”的泌乳素瘤患者的长期随访

Long-term follow-up of 'cured' prolactinoma patients after successful adenomectomy.

作者信息

Ciccarelli E, Ghigo E, Miola C, Gandini G, Muller E E, Camanni F

机构信息

Department of Biomedicine, University of Turin, Italy.

出版信息

Clin Endocrinol (Oxf). 1990 May;32(5):583-92. doi: 10.1111/j.1365-2265.1990.tb00901.x.

Abstract

The long-term follow-up (greater than or equal to 4 years) of clinical, hormonal and radiological aspects in 22 'cured' prolactinoma patients after adenomectomy was studied. Dynamic secretion of PRL and TSH was also evaluated, in order to identify the persistence of any underlying abnormality of hypothalamic pituitary control and to predict relapses. A relapse into hyperprolactinaemia was shown in 36% of patients 5-90 months (mean 46) after surgery. This was accompanied by reappearance of clinical symptoms but not by the radiological demonstration of the adenoma in any patients. A significant PRL rise after domperidone, a dopaminergic antagonist drug, was shown in cured patients after surgery (mean +/- SEM peak, 2977 +/- 645 mU/l) but this was markedly lower than that observed in control subjects (5732 +/- 440 mU/l). In fact, normal PRL increments were shown in only 6/16 (37%) patients. TSH hyper-responsiveness to domperidone normalized in only 46% of patients. Similar PRL responses to those obtained with domperidone were shown when a TRH test was given. A relapse into hyperprolactinaemia was observed in six of ten (60%) non-responders to domperidone and in four of seven (57%) non-responders to TRH, whereas six normal responders to domperidone and TRH had not relapsed at that time. Plasma PRL levels during pregnancy showed increments lower than those observed in normal pregnant women only in domperidone and TRH non-responder patients. These results indicate that a relapse into hyperprolactinaemia and a blunted PRL rise during pregnancy were present only in patients with persistently reduced PRL response to dynamic tests.

摘要

对22例腺瘤切除术后“治愈”的催乳素瘤患者进行了临床、激素和影像学方面的长期随访(大于或等于4年)。还评估了PRL和TSH的动态分泌,以确定下丘脑 - 垂体控制的任何潜在异常是否持续存在,并预测复发情况。36%的患者在术后5 - 90个月(平均46个月)复发为高催乳素血症。这伴随着临床症状的再次出现,但所有患者均未出现腺瘤的影像学表现。术后治愈的患者在给予多巴胺能拮抗剂多潘立酮后PRL显著升高(平均±SEM峰值,2977±645 mU/l),但明显低于对照组(5732±440 mU/l)。实际上,仅6/16(37%)的患者PRL正常升高。TSH对多潘立酮的高反应性仅在46%的患者中恢复正常。给予TRH试验时,PRL的反应与多潘立酮试验相似。在对多潘立酮无反应的10例患者中有6例(60%)、对TRH无反应的7例患者中有4例(57%)复发为高催乳素血症,而对多潘立酮和TRH反应正常的6例患者当时未复发。仅在对多潘立酮和TRH无反应的患者中,妊娠期间血浆PRL水平的升高低于正常孕妇。这些结果表明,仅在对动态试验PRL反应持续降低的患者中出现高催乳素血症复发和妊娠期间PRL升高减弱的情况。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验